| Literature DB >> 35852803 |
Johanne Naper Trønnes1, Angela Lupattelli1, Eivind Ystrom1,2,3, Hedvig Nordeng1,4.
Abstract
Importance: Few studies have examined the neurodevelopmental consequences of prenatal exposure to opioid analgesics. Therefore, it is necessary to gain knowledge to inform clinical decisions for pregnant women with moderate to severe pain. Objective: To investigate fifth-grade scholastic skills in children with prenatal exposure to opioid analgesics. Design, Setting, and Participants: A cohort study was conducted based on data from the Norwegian Mother, Father, and Child Cohort (1999-2008). These data were linked to the Medical Birth Registry of Norway, and data from Statistics Norway included 64 256 live-born singletons, born to 54 568 mothers who reported pain during pregnancy, were analyzed. The study was conducted from July 1 to December 15, 2021. Exposures: Self-reported exposure to opioid analgesics during pregnancy, characterized in terms of any exposure, the exposure timing, and the exposure duration. Main Outcomes and Measures: Scores from 3 national tests for children in fifth grade. The tests measured scholastic skills in literacy, numeracy, and the English language. Test scores were standardized to z scores. Differences in z scores were compared between children of mothers exposed to opioid analgesics during pregnancy and children of mothers with only prepregnancy opioid exposure.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35852803 PMCID: PMC9297111 DOI: 10.1001/jamanetworkopen.2022.22425
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Figure. Flowchart to Achieve Study Samples
Norwegian Mother, Father, and Child Cohort Study (MoBa) children born in 1999-2001 were not included in the study owing to lack of consent, because they became age 18 years before the follow-up was completed in 2018. Conditions of exclusion can overlap. MBRN indicates Medical Birth Registry of Norway; OMT, opioid maintenance treatment (ie, women reporting use of drugs with Anatomical Therapeutic Chemical Classification code N07BC); Q1, first MoBa questionnaire; and Q3, third MoBa questionnaire.
Characteristics of the Study Sample According to Prenatal Opioid Exposure Status (N = 64 256)
| Characteristic | Exposure status, No. (%) | ||
|---|---|---|---|
| Exposed (n = 1483) | Prepregnancy exposed only (n = 731) | Unexposed (n = 62 042) | |
|
| |||
| Age at delivery, y | |||
| <25 | 155 (10.4) | 107 (14.6) | 7075 (11.4) |
| 25-29 | 473 (31.9) | 241 (32.9) | 21 041 (33.9) |
| 30-34 | 554 (37.4) | 271 (37.1) | 23 794 (38.4) |
| ≥35 | 301 (20.3) | 112 (15.4) | 10 132 (16.3) |
| Marital status | |||
| Married/cohabitant | 1410 (95.1) | 697 (95.4) | 59 865 (96.5) |
| Other | 66 (4.4) | 30 (4.1) | 1876 (3.0) |
| Missing | 7 (0.5) | 4 (0.5) | 301 (0.5) |
| Parity | |||
| Primiparous | 607 (40.9) | 400 (54.7) | 27 878 (44.9) |
| Multiparous | 876 (59.1) | 331 (45.3) | 34 164 (55.1) |
| Educational level | |||
| 10-y Primary school or less | 168 (11.3) | 81 (11.1) | 4955 (8.0) |
| Secondary/vocational school | 476 (32.1) | 242 (33.1) | 17 749 (28.6) |
| College or advanced degree | 835 (56.3) | 405 (55.4) | 38 912 (62.7) |
| Missing | 4 (0.3) | 3 (0.4) | 426 (0.7) |
| Family income, ITNR | |||
| <2 | 590 (39.8) | 290 (39.7) | 22 069 (35.6) |
| 2-3 | 689 (46.5) | 313 (42.8) | 28 876 (46.5) |
| ≥3 | 194 (13.1) | 123 (16.8) | 10 469 (16.9) |
| Missing | 10 (0.6) | 5 (0.7) | 628 (1.0) |
| Prepregnancy BMI, mean (SD) | 25.1 (4.9) | 24.8 (4.7) | 24.1 (4.3) |
| Missing | 36 (2.4) | 18 (2.5) | 1535 (2.5) |
| Smoking | |||
| No | 1033 (69.6) | 506 (69.2) | 46 083 (74.3) |
| Yes | 213 (14.4) | 111 (15.2) | 5795 (9.3) |
| Missing | 237 (16.0) | 114 (15.6) | 10 164 (16.4) |
| Alcohol | |||
| No | 1261 (85.0) | 648 (88.6) | 54 775 (88.3) |
| Yes | 52 (3.5) | 19 (2.6) | 1449 (2.3) |
| Missing | 170 (11.5) | 64 (8.8) | 5818 (9.4) |
| Symptoms of anxiety/depression score, mean (SD) | 1.4 (0.5) | 1.4 (0.4) | 1.3 (0.4) |
| Missing | 63 (4.2) | 24 (3.3) | 2067 (3.3) |
| Maternal chronic disease | |||
| No | 1188 (80.1) | 585 (80.0) | 53 917 (86.9) |
| Yes | 295 (19.9) | 146 (20.0) | 8125 (13.1) |
| Use of comedication | |||
| Acetaminophen | 728 (49.1) | 238 (32.6) | 17 811 (28.7) |
| Triptans | 80 (5.4) | 5 (0.7) | 475 (0.8) |
| NSAIDs | 210 (14.2) | 42 (5.8) | 2783 (4.5) |
| Antidepressants | 39 (2.6) | 11 (1.5) | 588 (1.0) |
| Benzodiazepines and benzodiazepinelike drugs | 46 (3.1) | 5 (0.7) | 252 (0.4) |
| Antiepileptic | 10 (0.7) | 4 (0.6) | 186 (0.3) |
| Antipsychotic | 22 (1.5) | 8 (1.1) | 368 (0.6) |
| Pain types reported during pregnancy, No. | |||
| 1 | 224 (15.1) | 86 (11.8) | 16 322 (26.3) |
| 2-3 | 502 (33.9) | 286 (39.1) | 27 530 (44.4) |
| ≥4 | 757 (51.0) | 359 (49.1) | 18 190 (29.3) |
|
| |||
| Sex | |||
| Boys | 740 (49.9) | 359 (49.1) | 31 422 (50.6) |
| Girls | 743 (50.1) | 372 (50.9) | 30 620 (49.4) |
| Preterm (<37 wk) | 99 (6.7) | 35 (4.8) | 2644 (4.3) |
| Missing | 5 (0.3) | 3 (0.4) | 248 (0.4) |
| Time of year the baby was born | |||
| January-June | 775 (52.3) | 381 (52.1) | 31 592 (50.9) |
| July-December | 708 (47.7) | 350 (47.9) | 30 450 (49.1) |
|
| |||
| Age, y | |||
| 25-29 | 398 (26.8) | 231 (31.6) | 17 516 (28.2) |
| 30-34 | 568 (38.3) | 263 (35.9) | 24 159 (38.9) |
| ≥35 | 514 (34.7) | 236 (32.3) | 20 235 (32.6) |
| Missing | 3 (0.2) | 1 (0.2) | 132 (0.2) |
| Educational level | |||
| 10 y Primary school or less | 199 (13.4) | 116 (15.9) | 6813 (11.0) |
| Secondary/vocational school | 688 (46.4) | 320 (43.8) | 26 597 (42.9) |
| College or advanced degree | 583 (39.3) | 285 (38.9) | 27 831 (44.8) |
| Missing | 13 (0.9) | 10 (1.4) | 801 (1.3) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); ITNR, income to needs ratio; NSAIDs, nonsteroidal anti-inflammatory drugs.
Educational level was reported in the child’s birth year.
Family income was assessed by ITNR (EU-60 [European standard on how to calculate income to needs ratio]) reported in the year before childbirth.
Smoking status was reported at the start of pregnancy.
Measured in the first Mother, Father, and Child Cohort Study (MoBa) questionnaire.
Symptoms of anxiety and depression were measured by a short version of the Hopkins Symptom Checklist in the first MoBa questionnaire.
Maternal chronic disease include asthma, diabetes, hypertension, other heart disease, epilepsy, thyroid disorder, or arthritis reported 6 months before pregnancy.
Association Between Timing and Duration of Prenatal Exposure to Opioid Analgesics and Scholastic Skills Among Children in Fifth Grade Compared With Children of Mothers With Prepregnancy Exposure
| Characteristic | No. | β (95% CI) | ||
|---|---|---|---|---|
| Crude | Weighted | |||
|
| ||||
| Prepregnancy exposed only | 721 | 0.21 (1.0) | 1 [Reference] | 1 [Reference] |
| Exposed | 1445 | 0.15 (1.0) | 0.06 (−0.15 to 0.03) | −0.06 (−0.16 to 0.04) |
| By timing of exposure, trimester | ||||
| First | 671 | 0.09 (1.0) | −0.12 (−0.23 to −0.02) | −0.13 (−0.25 to −0.01) |
| Second | 783 | 0.17 (1.0) | −0.04 (−0.14 to 0.05) | −0.05 (−0.16 to 0.05) |
| Third | 486 | 0.18 (1.0) | −0.04 (−0.14 to 0.07) | −0.03 (−0.15 to 0.09) |
| By duration of exposure, intervals | ||||
| 1 | 917 | 0.18 (1.0) | −0.03 (−0.13 to 0.06) | −0.03 (−0.13 to 0.07) |
| 2-3 | 313 | 0.09 (1.0) | −0.13 (−0.26 to −0.00) | −0.19 (−0.35 to −0 04) |
| ≥4 | 215 | 0.12 (1.0) | −0.09 (−0.24 to 0.06) | −0.02 (−0.21 to 0.16) |
|
| ||||
| Prepregnancy exposed only | 722 | 0.21 (1.0) | 1 [Reference] | 1 [Reference] |
| Exposed | 1469 | 0.11 (1.0) | −0.09 (−0.18 to −0.01) | −0.08 (−0.17 to 0.01) |
| By timing of exposure, trimester | ||||
| First | 677 | 0.05 (1.0) | −0.16 (−0.26 to −0.06) | −0.14 (−0.25 to −0.04) |
| Second | 800 | 0.15 (1.0) | −0.06 (−0.15 to 0.04) | −0.06 (−0.16 to 0.04) |
| Third | 492 | 0.13 (1.0) | −0.08 (−0.18 to 0.04) | −0.05 (−0.18 to 0.07) |
| By duration of exposure, intervals | ||||
| 1 | 929 | 0.14 (1.0) | −0.07 (−0.16 to 0.03) | −0.06 (−0.16 to 0.03) |
| 2-3 | 322 | 0.05 (1.0) | −0.16 (−0.29 to −0.03) | −0.19 (−0.34 to −0.05) |
| ≥4 | 218 | 0.10 (1.0) | −0.10 (−0.25 to 0.04) | −0.05 (−0.25 to 0.14) |
|
| ||||
| Prepregnancy exposed only | 718 | 0.07 (1.0) | 1 [Reference] | 1 [Reference] |
| Exposed | 1444 | 0.08 (1.0) | −0.02 (−0.11 to 0.07) | −0.04 (−0.13 to 0.06) |
| By timing of exposure, trimester | ||||
| First | 672 | 0.01 (1.0) | −0.06 (−0.17 to 0.04) | −0.06 (−0.17 to 0.06) |
| Second | 780 | 0.08 (1.0) | 0.01 (−0.09 to 0.11) | −0.02 (−0.13 to 0.09) |
| Third | 484 | 0.08 (1.0) | 0.01 (−0.11 to 0.12) | −0.02 (−0.15 to 0.10) |
| By duration of exposure, intervals | ||||
| 1 | 917 | 0.05 (1.0) | −0.02 (−0.12 to 0.08) | −0.03 (−0.13 to 0.06) |
| 2-3 | 313 | 0.01 (1.0) | −0.07 (−0.20 to 0.07) | −0.11 (−0.26 to 0.05) |
| ≥4 | 214 | 0.11 (1.0) | 0.04 (−0.12 to 0.19) | 0.12 (−0.10 to 0.35) |
β, standardized mean difference in test scores.
One interval corresponds to a 4-week period, but not necessarily consecutive use in that period.
Timing and Duration of Prenatal Exposure to Opioid Analgesics and Scholastic Skills Among Children in Fifth Grade Compared With Unexposed Children
| Characteristic | No. | β (95% CI) | ||
|---|---|---|---|---|
| Crude | Weighted | |||
|
| ||||
| Unexposed | 60 709 | 0.21 (1.0) | 1 [Reference] | 1 [Reference] |
| Exposed | 1445 | 0.15 (1.0) | −0.05 (−0.10 to 0.00) | 0.01 (−0.06 to 0.04) |
| By timing of exposure, trimester | ||||
| First | 671 | 0.09 (1.0) | −0.12 (−0.19 to −0.04) | −0.06 (−0.14 to 0.01) |
| Second | 783 | 0.17 (1.0) | −0.04 (−0.11 to 0.03) | 0.01 (−0.06 to 0.08) |
| Third | 486 | 0.18 (1.0) | −0.03 (−0.11 to 0.06) | 0.00 (−0.09 to 0.08) |
| By duration of exposure, intervals | ||||
| 1 | 917 | 0.18 (1.0) | −0.02 (−0.09 to 0.04) | 0.02 (−0.04 to 0.08) |
| 2-3 | 313 | 0.09 (1.0) | −0.13 (−0.23 to −0.02) | −0.09 (−0.20 to 0.02) |
| ≥4 | 215 | 0.12 (1.0) | −0.08 (−0.21 to 0.04) | 0.01 (−0.11 to 0.14) |
|
| ||||
| Unexposed | 61 450 | 0.20 (1.0) | 1 [Reference] | 1 [Reference] |
| Exposed | 1469 | 0.11 (0.1) | −0.09 (−0.14 to −0.04) | −0.02 (−0.07 to 0.03) |
| By timing of exposure, trimester | ||||
| First | 677 | 0.05 (1.0) | −0.15 (−0.23 to −0.08) | −0.06 (−0.13 to 0.02) |
| Second | 800 | 0.15 (1.0) | −0.05 (−0.12 to 0.02) | 0.01 (−0.06 to 0.08) |
| Third | 492 | 0.13 (1.0) | −0.07 (−0.16 to 0.02) | 0.00 (−0.08 to 0.09) |
| By duration of exposure, intervals | ||||
| 1 | 929 | 0.14 (1.0) | −0.06 (−0.13 to 0.00) | −0.01 (−0.07 to 0.06) |
| 2-3 | 322 | 0.05 (1.0) | −0.16 (−0.27 to −0.05) | −0.11 (−0.22 to 0.01) |
| ≥4 | 218 | 0.10 (1.0) | −0.10 (−0.23 to 0.02) | 0.03 (−0.09 to 0.16) |
|
| ||||
| Unexposed | 60 976 | 0.08 (1.0) | 1 [Reference] | 1 [Reference] |
| Exposed | 1444 | 0.05 (1.0) | −0.03 (−0.08 to 0.02) | −0.01 (−0.07 to 0.04) |
| By timing of exposure, trimester | ||||
| First | 672 | 0.01 (1.0) | −0.07 (−0.14 to 0.01) | −0.03 (−0.11 to 0.04) |
| Second | 780 | 0.08 (1.0) | 0.00 (−0.07 to 0.07) | 0.00 (−0.07 to 0.08) |
| Third | 484 | 0.08 (1.0) | 0.00 (−0.09 to 0.09) | 0.00 (−0.08 to 0.09) |
| By duration of exposure, intervals | ||||
| 1 | 917 | 0.05 (1.0) | −0.03 (−0.09 to 0.04) | −0.01 (−0.07 to 0.06) |
| 2-3 | 313 | 0.01 (1.0) | −0.07 (−0.19 to 0.04) | −0.08 (−0.19 to 0.04) |
| ≥4 | 214 | 0.11 (1.0) | 0.03 (−0.10 to 0.16) | 0.06 (−0.08 to 0.20) |
β, standardized mean difference in test scores.
One interval corresponds to a 4-week period, but not necessarily consecutive use in that period.